Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 48

1.

Combined HER3-EGFR score in triple-negative breast cancer provides prognostic and predictive significance superior to individual biomarkers.

Ogden A, Bhattarai S, Sahoo B, Mongan NP, Alsaleem M, Green AR, Aleskandarany M, Ellis IO, Pattni S, Li XB, Moreno CS, Krishnamurti U, Janssen EA, Jonsdottir K, Rakha E, Rida P, Aneja R.

Sci Rep. 2020 Feb 20;10(1):3009. doi: 10.1038/s41598-020-59514-1.

2.

A quantitative centrosomal amplification score predicts local recurrence in ductal carcinoma in situ.

Mittal K, Toss MS, Wei G, Kaur J, Choi DH, Melton BD, Osan RM, Milligy IM, Green AR, Janssen EAM, Søiland H, Gogineni K, Manne U, Rida P, Rakha EA, Aneja R.

Clin Cancer Res. 2020 Jan 14. pii: clincanres.1272.2019. doi: 10.1158/1078-0432.CCR-19-1272. [Epub ahead of print]

3.

Panoptic View of Prognostic Models for Personalized Breast Cancer Management.

Saini G, Mittal K, Rida P, Janssen EAM, Gogineni K, Aneja R.

Cancers (Basel). 2019 Sep 7;11(9). pii: E1325. doi: 10.3390/cancers11091325. Review.

4.

Machine learning-based prediction of breast cancer growth rate in vivo.

Bhattarai S, Klimov S, Aleskandarany MA, Burrell H, Wormall A, Green AR, Rida P, Ellis IO, Osan RM, Rakha EA, Aneja R.

Br J Cancer. 2019 Sep;121(6):497-504. doi: 10.1038/s41416-019-0539-x. Epub 2019 Aug 9.

PMID:
31395950
5.

A whole slide image-based machine learning approach to predict ductal carcinoma in situ (DCIS) recurrence risk.

Klimov S, Miligy IM, Gertych A, Jiang Y, Toss MS, Rida P, Ellis IO, Green A, Krishnamurti U, Rakha EA, Aneja R.

Breast Cancer Res. 2019 Jul 29;21(1):83. doi: 10.1186/s13058-019-1165-5.

6.

Prognostic Role of Androgen Receptor in Triple Negative Breast Cancer: A Multi-Institutional Study.

Bhattarai S, Klimov S, Mittal K, Krishnamurti U, Li XB, Oprea-Ilies G, Wetherilt CS, Riaz A, Aleskandarany MA, Green AR, Ellis IO, Cantuaria G, Gupta M, Manne U, Agboola J, Baskovich B, Janssen EAM, Callagy G, Walsh EM, Mehta A, Dogra A, Shet T, Gajaria P, Traina T, Nggada HA, Omonisi A, Ahmed SA, Rakha EA, Rida P, Aneja R.

Cancers (Basel). 2019 Jul 17;11(7). pii: E995. doi: 10.3390/cancers11070995.

7.

Disadvantaged neighborhoods and racial disparity in breast cancer outcomes: the biological link.

Saini G, Ogden A, McCullough LE, Torres M, Rida P, Aneja R.

Cancer Causes Control. 2019 Jul;30(7):677-686. doi: 10.1007/s10552-019-01180-4. Epub 2019 May 20. Review.

PMID:
31111277
8.

Time will tell: Circadian clock dysregulation in triple negative breast cancer.

Rida P, Syed MI, Aneja R.

Front Biosci (Schol Ed). 2019 Mar 1;11:178-192. Review.

PMID:
30844743
9.

Targeting risk factors for reducing the racially disparate burden in breast cancer.

Wright N, Akinyemiju T, Subhedar P, Rida P, Aneja R.

Front Biosci (Schol Ed). 2019 Mar 1;11:136-160. Review.

PMID:
30844741
10.

The molecular mechanisms underlying reduced E-cadherin expression in invasive ductal carcinoma of the breast: high throughput analysis of large cohorts.

Alsaleem M, Toss MS, Joseph C, Aleskandarany M, Kurozumi S, Alshankyty I, Ogden A, Rida PCG, Ellis IO, Aneja R, Green AR, Mongan NP, Rakha EA.

Mod Pathol. 2019 Jul;32(7):967-976. doi: 10.1038/s41379-019-0209-9. Epub 2019 Feb 13.

PMID:
30760857
11.

Panoptic Overview of Triple-Negative Breast Cancer in Nigeria: Current Challenges and Promising Global Initiatives.

Wright N, Rida P, Rakha E, Agboola A, Aneja R.

J Glob Oncol. 2018 Jul;4:1-20. doi: 10.1200/JGO.17.00116. Review.

12.

Prognostic significance of tumor-infiltrating lymphocytes in ductal carcinoma in situ of the breast.

Toss MS, Miligy I, Al-Kawaz A, Alsleem M, Khout H, Rida PC, Aneja R, Green AR, Ellis IO, Rakha EA.

Mod Pathol. 2018 Aug;31(8):1226-1236. doi: 10.1038/s41379-018-0040-8. Epub 2018 Mar 20.

13.

Pharmacokinetic-pharmacodynamic correlations in the development of ginger extract as an anticancer agent.

Mukkavilli R, Yang C, Tanwar RS, Saxena R, Gundala SR, Zhang Y, Ghareeb A, Floyd SD, Vangala S, Kuo WW, Rida PCG, Aneja R.

Sci Rep. 2018 Feb 14;8(1):3056. doi: 10.1038/s41598-018-21125-2.

14.

First international TNBC conference meeting report.

Rida P, Ogden A, Ellis IO, Varga Z, Wolff AC, Traina TA, Hatzis C, Palmer JR, Ambrosone CB, Lehmann BD, Nanda R, Montgomery Rice V, Brawley OW, Torres MA, Rakha E, Aneja R.

Breast Cancer Res Treat. 2018 Jun;169(3):407-412. doi: 10.1007/s10549-018-4692-3. Epub 2018 Feb 8.

15.

Novel immunohistochemistry-based signatures to predict metastatic site of triple-negative breast cancers.

Klimov S, Rida PC, Aleskandarany MA, Green AR, Ellis IO, Janssen EA, Rakha EA, Aneja R.

Br J Cancer. 2017 Sep 5;117(6):826-834. doi: 10.1038/bjc.2017.224. Epub 2017 Jul 18.

16.

Centrosome amplification: a suspect in breast cancer and racial disparities.

Ogden A, Rida PCG, Aneja R.

Endocr Relat Cancer. 2017 Sep;24(9):T47-T64. doi: 10.1530/ERC-17-0072. Epub 2017 May 17. Review.

17.

Application of Combination High-Throughput Phenotypic Screening and Target Identification Methods for the Discovery of Natural Product-Based Combination Drugs.

Isgut M, Rao M, Yang C, Subrahmanyam V, Rida PCG, Aneja R.

Med Res Rev. 2018 Mar;38(2):504-524. doi: 10.1002/med.21444. Epub 2017 May 16. Review.

PMID:
28510271
18.

Tackling intra- and inter-tumor heterogeneity to combat triple negative breast cancer.

Wright N, Rida PCG, Aneja R.

Front Biosci (Landmark Ed). 2017 Jun 1;22:1549-1580. Review.

PMID:
28410132
19.

Multinucleated polyploidy drives resistance to Docetaxel chemotherapy in prostate cancer.

Mittal K, Donthamsetty S, Kaur R, Yang C, Gupta MV, Reid MD, Choi DH, Rida PCG, Aneja R.

Br J Cancer. 2017 Apr 25;116(9):1186-1194. doi: 10.1038/bjc.2017.78. Epub 2017 Mar 23.

20.

Prognostic value of CA20, a score based on centrosome amplification-associated genes, in breast tumors.

Ogden A, Rida PC, Aneja R.

Sci Rep. 2017 Mar 21;7(1):262. doi: 10.1038/s41598-017-00363-w.

Supplemental Content

Loading ...
Support Center